Cancer Endorsement Maintenance Phase 2
Colon Measures Workgroup
Monday, May 7, 2012
3:30 pm ET

AGENDA

3:30 pm   Welcome and Introductions
           Angela Franklin, JD Senior Director
           Lindsey Tighe, MS, Project Manager
           Adeela Khan, MPH, Project Analyst

3:35 pm   Workgroup Review of Colon Measures
           • 0392: Colorectal Cancer Resection Pathology Reporting- pT category
              (primary tumor) and pN category (regional lymph nodes) with histologic
              grade (AMA-PCPI)
           • 0223: Adjuvant chemotherapy is considered or administered within 4
              months (120 days) of surgery to patients under the age of 80 with AJCC
              III (lymph node positive) colon cancer (ACS)
           • 0225: At least 12 regional lymph nodes are removed and pathologically
              examined for resected colon cancer (ACS)
           • 0385: Oncology: Chemotherapy for Stage IIIA through IIIC Colon
              Cancer Patients (AMA-PCPI)
           • 1859: KRAS gene mutation testing performed for patients with
              metastatic colorectal cancer who receive anti-epidermal growth factor
              receptor monoclonal antibody therapy (ASCO)
           • 1860: Anti-epidermal growth factor receptor monoclonal antibody
              therapy not received by metastatic colorectal cancer patients with KRAS
              gene mutation (ASCO)

4:55 pm   Next Steps

5:00 pm   Adjourn

Please use the following information to access the conference call line:
Dial-in Number: 1-877-604-9674
Conference ID: 2284842
Event Title: Cancer SC Phase 2 - Colon Measures Workgroup
Please note that the registration link will be activated 15 minutes prior to the meeting.